Your Impact on Cancer Research in 2022

Research is central to what we do at Inova Schar Cancer Institute and helps improve patient care by increasing cure rates and prolonging the lives of patients with recurrent cancers. Your generosity helped propel us forward on so many important fronts – showing the power of philanthropy in action.

Thanks to your investment in cancer research at Inova Schar Cancer Institute, we had a record 970 active studies in 2022 – and a 41% patient increase enrolled compared to 2021.

These achievements would not be possible without your partnership. In this impact report, you will be able to read how your support has benefitted innovative initiatives in so many areas, including:

Funding new clinical studies and clinical trials, including five active trials focusing on cancer prevention and early detection in our new Inova Saville Cancer Screening and Prevention Center that opened in May 2022

Recruiting Nagla Abdel Karim, MD, Ph.D., as Director of the Early Phase Developmental Therapeutics Program. This hire has drawn local and national attention, putting Inova Schar on the map as a renowned and groundbreaking research facility

Being the largest community-based enroller in the U.S. to a phase 3 breast cancer study for proton therapy versus standard photon radiation

Addressing healthcare inequities by expanding mobile clinics and clinical trials into underserved communities through our Inova Saville Cancer Screening and Prevention Center

This was truly a team effort to achieve what we did in 2022 – and more importantly it is a testament to the transformational impact your philanthropy has on research. You have our deepest gratitude.

Warmly, John Deeken, MD President

Inova Schar Cancer Institute